Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Steven_Kelly
|
| gptkbp:collaboratesWith |
gptkb:Moderna
|
| gptkbp:developedBy |
CAR-M (chimeric antigen receptor macrophage) therapies
|
| gptkbp:focusesOn |
immunotherapy
gene therapy chimeric antigen receptor macrophages |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Carl_June
gptkb:Bruce_Levine Michael Klichinsky Saar Gill |
| gptkbp:headquartersLocation |
gptkb:Philadelphia,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carisma Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableCase |
Phase 1 clinical trial for CT-0508
|
| gptkbp:notableProduct |
CT-0508
|
| gptkbp:originatedIn |
gptkb:University_of_Pennsylvania
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CARM
|
| gptkbp:target |
gptkb:cancer
solid tumors |
| gptkbp:website |
https://www.carismatx.com/
|
| gptkbp:bfsParent |
gptkb:ModernaTX,_Inc.
|
| gptkbp:bfsLayer |
7
|